Inkjet and micro-extrusion printing of an orodispersible film — dose precision from droplet counting, not weighing
Orodispersible film (ODF) 3D printing repurposes inkjet and micro-extrusion technology to deposit medicine the way a desktop printer deposits color — as a precisely metered fluid. This demands a fundamentally different formulation strategy than tablets or capsules: the API must exist as a true solution or nanosuspension in a low-viscosity, low-surface-tension ink compatible with piezoelectric or micro-extrusion print heads.
Piezoelectric inkjet printheads impose strict physicochemical requirements absent from conventional oral solid dosage formulation:
• Viscosity: 5–20 mPa·s at the operating temperature — far lower than SSE pastes (2,000–50,000 mPa·s) or FDM melts; achieved by keeping polymer content low (2–8% w/w film-former) and using a low-viscosity solvent system (water, water/ethanol) • Surface tension: 25–45 mN/m, tuned with small amounts of surfactant (polysorbate 80, poloxamer) — too high causes satellite droplet formation and misdirected jetting; too low causes wetting/spreading beyond the intended dose zone • Particle-free or sub-micron: any API particulate must be smaller than roughly 1/50th of the nozzle diameter (typical inkjet nozzles are 20–50 µm) to avoid clogging — this drives a strong preference for water-soluble APIs or nanomilled suspensions (e.g., wet-media milling to D90 <500 nm) • Z number (Z = 1/Oh, inverse Ohnesorge number, combining viscosity, density, surface tension, and nozzle diameter): jettable ink formulations target Z between 1 and 10; outside this range, ink either fails to form a droplet or fragments into satellite droplets that degrade dose accuracy
Film-forming polymer selection: pullulan (a neutral-tasting, fast-dissolving polysaccharide) and low-viscosity HPMC (E3, E5 grades) dominate ODF ink formulations because they combine low solution viscosity at usable concentrations with strong, flexible dried-film mechanical properties.
Because inkjet dose is set by counting droplets rather than weighing powder, the smallest addressable dose increment can be sub-microgram — enabling ODF 3D printing for ultra-low-dose, high-potency APIs (e.g., certain hormone therapies, pediatric cardiovascular drugs) where conventional powder blending cannot achieve adequate content uniformity.
Unlike printing on paper, the "canvas" for an orodispersible film must itself be pharmaceutically acceptable, orally disintegrable, and physically compatible with holding wet ink in place without excessive spreading — so substrate design is as much a formulation problem as the ink itself.
Integrated edible backing film: a thin (20–40 µm), drug-free or low-dose pullulan/HPMC film is solvent-cast in bulk by conventional means, then loaded onto the 3D printer bed. The API-loaded ink is printed directly onto this backing, becoming a permanent, orally consumed part of the final dosage form. This approach benefits from decades of established ODF manufacturing science for the backing film while gaining print-based dose precision for the API layer.
Removable (non-oral) liner: ink is printed onto a non-edible, low-surface-energy liner (silicone-coated PET), dried, then the free-standing drug film is peeled away for packaging (e.g., into a blister or sachet) without any backing material remaining in the final product. This minimizes excipient burden and disintegration time (no separate backing layer to dissolve) but requires the printed drug/polymer layer to have sufficient mechanical integrity to be self-supporting when peeled — typically requiring at least 15–20% polymer content in the printed ink layer itself.
Wetting control: substrate surface energy (measured by contact angle goniometry) is matched to ink surface tension so that each droplet spreads to a controlled, reproducible spot diameter (typically 100–300 µm) without excessive lateral bleeding into neighboring dose zones — critical when multiple different-dose films are printed on the same sheet.
The defining advantage of inkjet/micro-extrusion ODF printing over cast-film manufacturing is that dose becomes a direct, digitally controllable function of print passes and ink concentration — replacing the assumption of uniform drug distribution across a cast film with an explicitly metered, per-unit dose calculation.
Total delivered dose is computed directly from print parameters rather than inferred from a cast, weighed film:
Dose (mg) = (drops per mm² per pass) × (dose zone area, mm²) × (droplet volume, nL) × (number of passes) × (ink concentration, mg/mL) × 10⁻⁶
Each variable is independently and precisely controllable in firmware:
• Drops per mm² per pass: set by nozzle spacing and printhead resolution (commonly 300–1200 dpi equivalent) • Dose zone area: defined in the print job as a bounded region on the substrate — smaller zones concentrate more dose per unit area, useful for high-potency, low-volume APIs • Number of passes: the primary patient-titration lever — printing the same ink 1×, 3×, or 8× over the identical dose zone linearly multiplies delivered dose, directly analogous to how infill/volume scaling works for solid printlets (see companion module on dose titration by print geometry) • Ink concentration: a secondary, batch-level lever — fixed per feedstock lot, analogous to filament drug loading in FDM printing
Because both drop volume and jetting frequency are calibrated and monitored in real time by the printhead's own drive electronics (piezo actuation voltage/waveform is closed-loop controlled), dose reproducibility across passes and across print runs is markedly tighter than the film-thickness variability inherent to conventional solvent-cast ODF manufacturing.
Every printed layer must be dried before the next pass is deposited, or droplets from successive passes will merge, spread, and redistribute drug mass beyond the intended dose zone — destroying the precision the printing process was designed to deliver.
Two drying technologies are typically integrated directly into the print carriage or immediately downstream on a conveyor:
• Convective warm-air drying: a directed air jet (40–60°C) passes over the freshly printed layer for 2–8 seconds — sufficient to flash off the low-boiling solvent fraction (water, ethanol) before the printhead returns for the next pass, without exposing the API to prolonged thermal stress • IR (infrared) panel drying: radiant heating penetrates the thin printed layer more uniformly than convective air alone, often preferred for higher print-pass-count films (thicker cumulative deposit) where convective drying alone would be too slow to keep pace with print speed
Drying rate must be balanced against two competing risks: too fast, and rapid solvent loss can cause film cracking or API recrystallization at the surface (affecting redispersion/dissolution behavior); too slow, and successive droplets coalesce laterally, blurring the intended dose-zone boundary and degrading unit-to-unit dose reproducibility.
Final moisture specification: the fully printed, multi-pass film is typically dried to <5% residual solvent (thermogravimetric analysis or Karl Fischer titration), consistent with ICH Q3C residual solvent limits and standard ODF shelf-stability requirements.
The clinical value proposition of an orodispersible film rests on rapid, complete disintegration in the oral cavity — typically within 30 seconds — enabling dosing without water, improved adherence for dysphagic or pediatric/geriatric patients, and, for suitably permeable APIs, direct sublingual or buccal absorption that bypasses hepatic first-pass metabolism.
ODF disintegration is assessed by a slide-frame method (a film is placed on a wire mesh over dissolution medium/simulated saliva, and time to visually complete disintegration is recorded) or by a modified Ph. Eur. 2.9.1 disintegration apparatus adapted for thin films. Target: complete disintegration within 30 seconds, with premium formulations achieving 5–15 seconds.
Key determinants of disintegration time within this printed-film system: • Film thickness (directly set by print-pass count): thinner films (fewer passes, lower dose) disintegrate faster than thicker, higher-pass, higher-dose films — an inherent trade-off the formulator must balance against required drug loading per unit area • Polymer choice: pullulan disintegrates faster than higher-molecular-weight HPMC grades at equivalent thickness • Plasticizer content: glycerol/PEG improve flexibility (reducing brittleness/cracking on handling) but can modestly slow disintegration at higher concentrations
Dissolution testing (where full quantitative release profiling is required) uses a modified USP apparatus with a film-holding accessory in 900 mL or smaller-volume biorelevant medium, given the small total mass of most ODFs (typically 20–80 mg total film weight).
For APIs with adequate lipophilicity and low first-pass extraction ratio contraindications (e.g., certain triptans, ondansetron, buprenorphine), sublingual absorption via the highly vascularized sublingual mucosa can achieve therapeutic plasma concentrations within 2–5 minutes — markedly faster than oral tablet absorption, while avoiding first-pass hepatic metabolism that would otherwise reduce bioavailability.